CA
BMRN icon

Cetera Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cetera Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,300
Closed -$63.8K – 1657
2022
Q4 		$63.8K Buy
+13,300
New +$1.25M ﹤0.01% 1534

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cetera Advisors's BMRN Position: Q1 2024 in Review

Cetera Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 176% in Q1 2024, buying an estimated $387K and bringing the position to 6,785 shares worth $593K. The position accounts for ﹤0.01% of the portfolio, ranked #1497.

Cetera Advisors first reported a position in BMRN in Q2 2022 and has held it in 6 quarters since. The position peaked at $1.61M in Q4 2022. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • Cetera Advisors held 6,785 shares of BioMarin Pharmaceuticals worth $593K as of Q1 2024.
  • Cetera Advisors bought 4,324 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $387K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Cetera Advisors's portfolio in Q1 2024, its #1497 holding.
  • Cetera Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2022 and has held it in 6 quarters since.
  • Cetera Advisors's BioMarin Pharmaceuticals position peaked at $1.61M in Q4 2022.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.